Compare COKE & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COKE | SNN |
|---|---|---|
| Founded | 1902 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Industrial Specialties |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 14.0B |
| IPO Year | N/A | 1999 |
| Metric | COKE | SNN |
|---|---|---|
| Price | $165.94 | $32.60 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $32.83 |
| AVG Volume (30 Days) | 453.3K | ★ 489.3K |
| Earning Date | 10-29-2025 | 03-02-2026 |
| Dividend Yield | 0.60% | ★ 2.25% |
| EPS Growth | 22.14 | ★ 59.91 |
| EPS | ★ 7.03 | 0.56 |
| Revenue | ★ $7,070,308,000.00 | $5,944,000,000.00 |
| Revenue This Year | N/A | $7.78 |
| Revenue Next Year | N/A | $5.13 |
| P/E Ratio | ★ $22.90 | $58.43 |
| Revenue Growth | 4.22 | ★ 5.35 |
| 52 Week Low | $105.21 | $23.69 |
| 52 Week High | $168.21 | $38.79 |
| Indicator | COKE | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 67.36 | 41.84 |
| Support Level | $159.13 | $32.97 |
| Resistance Level | $168.21 | $33.60 |
| Average True Range (ATR) | 3.73 | 0.41 |
| MACD | -1.32 | 0.10 |
| Stochastic Oscillator | 70.70 | 21.21 |
Coca-Cola Consolidated Inc distributes, markets and manufactures nonalcoholic beverages. It offer a range of nonalcoholic beverage products and flavors, including both sparkling and still beverages. Sparkling beverages are carbonated beverages and the Company's principal sparkling beverage is Coca Cola. Still beverages include energy products and noncarbonated beverages such as bottled water, ready-to-drink tea, ready-to-drink coffee, enhanced water, juices and sports drinks. The Company has three operating segments: Nonalcoholic Beverages, All Other and Eliminations. key revenue is generated from Nonalcoholic Beverages.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.